Rachel Vatnsdal
Stock Analyst at JP Morgan
(3.39)
# 987
Out of 5,154 analysts
68
Total ratings
55.32%
Success rate
16.39%
Average return
Main Sectors:
Stocks Rated by Rachel Vatnsdal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVTY Revvity | Maintains: Neutral | $100 → $105 | $91.34 | +14.96% | 5 | Feb 3, 2026 | |
| ADPT Adaptive Biotechnologies | Maintains: Overweight | $17 → $20 | $14.86 | +34.59% | 6 | Nov 6, 2025 | |
| HSIC Henry Schein | Maintains: Overweight | $80 → $76 | $77.60 | -2.06% | 4 | Aug 7, 2025 | |
| AVTR Avantor | Maintains: Overweight | $17 → $14 | $8.17 | +71.36% | 1 | Aug 4, 2025 | |
| ILMN Illumina | Maintains: Neutral | $85 → $100 | $124.62 | -19.76% | 1 | Aug 1, 2025 | |
| CAI Caris Life Sciences | Initiates: Overweight | $31 | $18.59 | +66.76% | 1 | Jul 14, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $12 → $9 | $20.81 | -56.75% | 4 | May 9, 2025 | |
| TWST Twist Bioscience | Maintains: Underweight | $40 → $33 | $46.94 | -29.70% | 2 | May 6, 2025 | |
| RGEN Repligen | Maintains: Overweight | $200 → $190 | $119.99 | +58.35% | 6 | Apr 29, 2025 | |
| NVST Envista Holdings | Maintains: Neutral | $20 → $19 | $26.86 | -29.26% | 4 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $380 → $390 | $302.54 | +28.91% | 4 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $55 | $52.26 | +5.24% | 3 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $55 | $91.20 | -39.69% | 1 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $165 → $160 | $115.07 | +39.05% | 6 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $650 → $670 | $501.97 | +33.47% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $17 → $20 | $5.15 | +288.35% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,300 → $1,400 | $1,209.65 | +15.74% | 2 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.38 | - | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $60 → $90 | $36.68 | +145.37% | 2 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $250 → $270 | $195.50 | +38.11% | 4 | Dec 20, 2023 |
Revvity
Feb 3, 2026
Maintains: Neutral
Price Target: $100 → $105
Current: $91.34
Upside: +14.96%
Adaptive Biotechnologies
Nov 6, 2025
Maintains: Overweight
Price Target: $17 → $20
Current: $14.86
Upside: +34.59%
Henry Schein
Aug 7, 2025
Maintains: Overweight
Price Target: $80 → $76
Current: $77.60
Upside: -2.06%
Avantor
Aug 4, 2025
Maintains: Overweight
Price Target: $17 → $14
Current: $8.17
Upside: +71.36%
Illumina
Aug 1, 2025
Maintains: Neutral
Price Target: $85 → $100
Current: $124.62
Upside: -19.76%
Caris Life Sciences
Jul 14, 2025
Initiates: Overweight
Price Target: $31
Current: $18.59
Upside: +66.76%
10x Genomics
May 9, 2025
Maintains: Neutral
Price Target: $12 → $9
Current: $20.81
Upside: -56.75%
Twist Bioscience
May 6, 2025
Maintains: Underweight
Price Target: $40 → $33
Current: $46.94
Upside: -29.70%
Repligen
Apr 29, 2025
Maintains: Overweight
Price Target: $200 → $190
Current: $119.99
Upside: +58.35%
Envista Holdings
Mar 6, 2025
Maintains: Neutral
Price Target: $20 → $19
Current: $26.86
Upside: -29.26%
Mar 6, 2025
Maintains: Neutral
Price Target: $380 → $390
Current: $302.54
Upside: +28.91%
Feb 25, 2025
Downgrades: Neutral
Price Target: $50 → $55
Current: $52.26
Upside: +5.24%
Feb 21, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $91.20
Upside: -39.69%
Nov 26, 2024
Maintains: Overweight
Price Target: $165 → $160
Current: $115.07
Upside: +39.05%
Sep 20, 2024
Maintains: Overweight
Price Target: $650 → $670
Current: $501.97
Upside: +33.47%
Aug 7, 2024
Maintains: Underweight
Price Target: $17 → $20
Current: $5.15
Upside: +288.35%
Aug 5, 2024
Maintains: Neutral
Price Target: $1,300 → $1,400
Current: $1,209.65
Upside: +15.74%
Apr 22, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.38
Upside: -
Feb 14, 2024
Upgrades: Overweight
Price Target: $60 → $90
Current: $36.68
Upside: +145.37%
Dec 20, 2023
Maintains: Overweight
Price Target: $250 → $270
Current: $195.50
Upside: +38.11%